Regulation of mitochondrial dynamics and energetics in the diabetic renal proximal tubule by the β2-adrenergic receptor agonist formoterol
- 1 November 2020
- journal article
- research article
- Published by American Physiological Society in American Journal of Physiology-Renal Physiology
- Vol. 319 (5) , F773-F779
Abstract
Diabetes is a prevalent metabolic disease that contributes to ∼50% of all end-stage renal disease and has limited treatment options. We previously demonstrated that the β2-adrenergic receptor agonist formoterol induced mitochondrial biogenesis and promoted recovery from acute kidney injury. Here, we assessed the effects of formoterol on mitochondrial dysfunction and dynamics in renal proximal tubule cells (RPTCs) treated with high glucose and in a mouse model of type 2 diabetes. RPTCs exposed to 17 mM glucose exhibited increased electron transport chain (ETC) complex I, II, III, and V protein levels and reduced ATP levels and uncoupled oxygen consumption rate compared with RPTCs cultured in the absence of glucose or osmotic controls after 96 h. ETC proteins, ATP, and oxygen consumption rate were restored in RPTCs treated with formoterol. RPTCs exposed to high glucose had increased phospho-dynamin-related protein 1 (Drp1), a mitochondrial fission protein, and decreased mitofusin 1 (Mfn1), a mitochondrial fusion protein. Formoterol treatment restored phospho-Drp1 and Mfn1 to control levels. Db/ db and nondiabetic ( db/m) mice (10 wk old) were treated with formoterol or vehicle for 3 wk and euthanized. Db/ db mice showed increased renal cortical ETC protein levels in complexes I, III, and V and decreased ATP; these changes were prevented by formoterol. Phospho-Drp1 was increased and Mfn1 was decreased in db/ db mice, and formoterol restored both to control levels. Together, these findings demonstrate that hyperglycemic conditions in vivo and exposure of RPTCs to high glucose similarly alter mitochondrial bioenergetic and dynamics profiles and that treatment with formoterol can reverse these effects. Formoterol may be a promising strategy for treating early stages of diabetic kidney disease.Keywords
Funding Information
- Southern Arizona VA Health Care System
- University of Arizona
- NIH (5T32ES00709137)
This publication has 32 references indexed in Scilit:
- Diabetic kidney diseases revisited: A new perspective for a new eraMolecular Metabolism, 2019
- Update of pathophysiology and management of diabetic kidney diseaseJournal of the Formosan Medical Association, 2018
- Mitochondrial dysfunction in diabetic kidney diseaseNature Reviews Nephrology, 2018
- Mitochondrial Dynamics in Mitochondrial DiseasesDiseases, 2016
- Hyperglycemia induced damage to mitochondrial respiration in renal mesangial and tubular cells: Implications for diabetic nephropathyRedox Biology, 2016
- Dynamin–Related Protein 1 Deficiency Improves Mitochondrial Fitness and Protects against Progression of Diabetic NephropathyJournal of the American Society of Nephrology, 2016
- The β2-Adrenoceptor Agonist Formoterol Stimulates Mitochondrial BiogenesisThe Journal of Pharmacology and Experimental Therapeutics, 2012
- A high-throughput respirometric assay for mitochondrial biogenesis and toxicityAnalytical Biochemistry, 2010
- Immunofluorescent imaging of β1- and β2-adrenergic receptors in rat kidneyKidney International, 2001
- Improved culture conditions stimulate gluconeogenesis in primary cultures of renal proximal tubule cellsAmerican Journal of Physiology-Cell Physiology, 1995